NCT05363904Completed
Atopic Dermatitis: Sub-Saharan Africa vs. Central Europe
Environmental Impact and Immune Responses in Atopic Dermatitis Patients in Central Europe and Sub-Saharan Africa: A Prospective Study
Source: ClinicalTrials.gov · Last updated 9 Jul 2025
Brief summary (registry, in English)
Many people are affected by atopic dermatitis (AD) worldwide. However, clinical studies on AD in Sub-Saharan Africa are rare and there is a lack of knowledge about possible differences in pathogenesis between European and African AD. This study will collect clinical and laboratory data with the aim to compare clinical characteristics and immune responses in AD patients in Sub-Saharan Africa and Central Europe. Furthermore, relevant allergens as well as the nasal, skin and gut micro- and mycobiome will be investigated.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 240 (actual)
- First submitted
- 4 Mar 2022
- Start date
- 30 Mar 2022
- Primary completion date
- 12 Mar 2025
- Lead sponsor
- University of Zurich
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT05363904
What you commit to
- Study type: Observational
- Participants enrolled: 240
- From 30 Mar 2022 to the primary completion date, 12 Mar 2025
- 3 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Systemic immunomodulatory/-suppressive treatment
- Glucocorticoids or immunosuppressants (last 4 weeks) or
- JAK inhibitors (last week) or
- Omalizumab (last 4 weeks) or
- Other biologicals e.g. dupilumab (last 2 months)
- Systemic antibiotic, antimycotic or antiviral treatment 4 weeks prior to start
- Phototherapy 4 weeks prior to start
- Undergoing surgery in the last 2 months
Other illness
- Known or suspected systemic immunosuppression because of disease
- Clinical signs of active bacterial, fungal or viral infection
- Infarction (e.g. stroke), embolism, or thrombosis in the last 2 months
- Inability to follow the study procedures e.g. due to language problems, dementia etc. of the participant
Other
- Active neoplasia
Who the study is looking for
- AD patients:
- Age: ≥18 years
- Written informed consent given after information about the research project
- Suffering from active atopic dermatitis
- No active skin disease other than atopic dermatitis
- No known active inflammatory disease other than atopic dermatitis/atopic diseases
- HC participants:
- Age: ≥18 years
- Written informed consent given after information about the research project
- No active skin disease
- No known atopic disease (atopic dermatitis, asthma, allergy, allergic rhinoconjuncitivitis)
- No known active inflammatory disease
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Zurich Coordinator of this site? Confirm its status | Zurich | Switzerland | Unknown status |
| University Hospital Joseph Raseta Befelatanana Coordinator of this site? Confirm its status | Antananarivo | Madagascar | Unknown status |
| Regional Dermatology Training Centre (RDTC) Coordinator of this site? Confirm its status | Moshi | Tanzania | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.